Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Lineage Cell Therapeutics (LCTX) over the last 14 years, with Q3 2025 value amounting to $7.5 million.

  • Lineage Cell Therapeutics' Non-cash Items fell 2105.26% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year decrease of 2105.26%. This contributed to the annual value of $8.2 million for FY2024, which is 68319.01% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Non-cash Items of $7.5 million as of Q3 2025, which was down 2105.26% from $8500.0 recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Non-cash Items peaked at $13.0 million during Q1 2023, and registered a low of $8500.0 during Q2 2025.
  • For the 5-year period, Lineage Cell Therapeutics' Non-cash Items averaged around $7.5 million, with its median value being $8.7 million (2021).
  • In the last 5 years, Lineage Cell Therapeutics' Non-cash Items soared by 68319.01% in 2024 and then crashed by 9991.9% in 2025.
  • Lineage Cell Therapeutics' Non-cash Items (Quarter) stood at $9.6 million in 2021, then tumbled by 85.79% to $1.4 million in 2022, then decreased by 23.24% to $1.0 million in 2023, then skyrocketed by 683.19% to $8.2 million in 2024, then dropped by 8.54% to $7.5 million in 2025.
  • Its last three reported values are $7.5 million in Q3 2025, $8500.0 for Q2 2025, and $9700.0 during Q1 2025.